Literature DB >> 21195670

Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice.

Adrian G Rosas-Taraco1, David M Higgins, Joaquín Sánchez-Campillo, Eric J Lee, Ian M Orme, Mercedes González-Juarrero.   

Abstract

In this study we demonstrate that it is possible to shift the immune system during a chronic infection with Mycobacterium tuberculosis. TGFβ and IL10 cytokines inhibit the Th1 response during chronic pulmonary infection with M. tuberculosis. We show that intrapulmonary delivery of siRNA targeting TGFβ1 is able to reduce the pulmonary bacillary load in mice chronically infected with M. tuberculosis: an effect that appears to be partly dependent on IL10 expression. To demonstrate this, we induced gene silencing of tgfβ1 in the lungs of wild type and IL10 knockout mice using a non-invasive aerosolized intrapulmonary delivery of siRNA targeting TGFβ1. Five days after the last treatment with siRNA, the levels of tgfb1 transcripts and TGFβ1 protein were reduced when compared with control groups treated with RNase-free water or non-targeting siRNA. Mice treated with siRNA also had increased expression of the antimicrobial mediators (NO and iNOS) which effectively reduced the bacterial load by 0.17 and 0.47 log(10) in C57BL/6 and IL-10 KO mice respectively when compared with their respective control mice. More importantly, the bacterial load in siRNA treated IL-10 KO mice four weeks after the last treatment remained 0.32 log(10) lower than in control mice.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195670      PMCID: PMC7238550          DOI: 10.1016/j.tube.2010.11.004

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  40 in total

1.  Tuberculosis vaccines: current progress.

Authors:  Ian M Orme
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  TGF-beta and fibrosis.

Authors:  M H Branton; J B Kopp
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

3.  Deactivation of macrophages by transforming growth factor-beta.

Authors:  S Tsunawaki; M Sporn; A Ding; C Nathan
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

4.  Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice.

Authors:  Andre L Moreira; Liana Tsenova; Melles Haile Aman; Linda-Gail Bekker; Sherry Freeman; Bande Mangaliso; Ulf Schröder; Jaishree Jagirdar; William N Rom; Michael G Tovey; Victoria H Freedman; Gilla Kaplan
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

5.  Enhanced macrophage activity in granulomatous lesions of immune mice challenged with Mycobacterium tuberculosis.

Authors:  Diane Ordway; Marisa Harton; Marcela Henao-Tamayo; Rose Montoya; Ian M Orme; Mercedes Gonzalez-Juarrero
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs.

Authors:  Shannon Sedberry Allen; Lynne Cassone; Todd M Lasco; David N McMurray
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice.

Authors:  Joanne Turner; Mercedes Gonzalez-Juarrero; Debi L Ellis; Randy J Basaraba; Andre Kipnis; Ian M Orme; Andrea M Cooper
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

8.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.

Authors:  Bao-jian Li; Qingquan Tang; Du Cheng; Chuan Qin; Frank Y Xie; Qiang Wei; Jun Xu; Yijia Liu; Bo-jian Zheng; Martin C Woodle; Nanshan Zhong; Patrick Y Lu
Journal:  Nat Med       Date:  2005-08-21       Impact factor: 53.440

9.  siRNA targeting the leader sequence of SARS-CoV inhibits virus replication.

Authors:  T Li; Y Zhang; L Fu; C Yu; X Li; Y Li; X Zhang; Z Rong; Y Wang; H Ning; R Liang; W Chen; L A Babiuk; Z Chang
Journal:  Gene Ther       Date:  2005-05       Impact factor: 5.250

10.  Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis.

Authors:  Atsushi Kitani; Ivan Fuss; Kazuhiko Nakamura; Fumiyuki Kumaki; Takashi Usui; Warren Strober
Journal:  J Exp Med       Date:  2003-10-13       Impact factor: 14.307

View more
  20 in total

1.  Inhalation of recombinant adenovirus expressing granulysin protects mice infected with Mycobacterium tuberculosis.

Authors:  J Ma; J Lu; H Huang; X Teng; M Tian; Q Yu; X Yuan; Y Jing; C Shi; J Li; X Fan
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

2.  IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis.

Authors:  Allison E Reeme; Halli E Miller; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2013-03-13       Impact factor: 3.131

3.  Stringent homology-based prediction of H. sapiens-M. tuberculosis H37Rv protein-protein interactions.

Authors:  Hufeng Zhou; Shangzhi Gao; Nam Ninh Nguyen; Mengyuan Fan; Jingjing Jin; Bing Liu; Liang Zhao; Geng Xiong; Min Tan; Shijun Li; Limsoon Wong
Journal:  Biol Direct       Date:  2014-04-08       Impact factor: 4.540

4.  Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery.

Authors:  Mercedes Gonzalez-Juarrero; Lisa K Woolhiser; Elizabeth Brooks; Mary Ann DeGroote; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

5.  An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice.

Authors:  Vandana Kaul; Debapriya Bhattacharya; Yogesh Singh; Luc Van Kaer; Marc Peters-Golden; William R Bishai; Gobardhan Das
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

6.  TGFβ restricts expansion, survival, and function of T cells within the tuberculous granuloma.

Authors:  Benjamin H Gern; Kristin N Adams; Courtney R Plumlee; Caleb R Stoltzfus; Laila Shehata; Albanus O Moguche; Kathleen Busman-Sahay; Scott G Hansen; Michael K Axthelm; Louis J Picker; Jacob D Estes; Kevin B Urdahl; Michael Y Gerner
Journal:  Cell Host Microbe       Date:  2021-03-11       Impact factor: 21.023

7.  Intratracheal Bleomycin Aerosolization: The Best Route of Administration for a Scalable and Homogeneous Pulmonary Fibrosis Rat Model?

Authors:  Alexandre Robbe; Alexandra Tassin; Justine Carpentier; Anne-Emilie Declèves; Zita Léa Mekinda Ngono; Denis Nonclercq; Alexandre Legrand
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

Review 8.  Tuberculosis drug discovery in the post-post-genomic era.

Authors:  Benoit Lechartier; Jan Rybniker; Alimuddin Zumla; Stewart T Cole
Journal:  EMBO Mol Med       Date:  2014-01-08       Impact factor: 12.137

Review 9.  Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Authors:  Dilara Kiran; Brendan K Podell; Mark Chambers; Randall J Basaraba
Journal:  Semin Immunopathol       Date:  2015-10-28       Impact factor: 9.623

10.  Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.

Authors:  Richard E Lee; Julian G Hurdle; Jiuyu Liu; David F Bruhn; Tanja Matt; Michael S Scherman; Bernd Meibohm; Erik C Böttger; Anne J Lenaerts; Pavan K Vaddady; Zhong Zheng; Jianjun Qi; Rashid Akbergenov; Sourav Das; Dora B Madhura; Chetan Rathi; Ashit Trivedi; Cristina Villellas; Robin B Lee; Samanthi L Waidyarachchi; Dianqing Sun; Michael R McNeil; Jose A Ainsa; Helena I Boshoff; Mercedes Gonzalez-Juarrero
Journal:  Nat Med       Date:  2014-01-26       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.